Page 6,748«..1020..6,7476,7486,7496,750..6,7606,770..»

Aeterna Zentaris: Phase 1 Results Show Perifosine's Activity Against Neuroblastoma

Posted: Published on June 21st, 2012

QUBEC CITY, June 21, 2012 /CNW Telbec/ - Aeterna Zentaris Inc. (AEZS) (TSX:AEZ) (the"Company") today announced that Phase 1 trial results for its oral PI3K/Akt inhibitor, perifosine, showed the drug's activity against chemo-resistant and radio-resistant neuroblastoma, while allowing good quality of life and sparing vital organs. Neuroblastoma is a type of childhood cancer which usually begins in nerve tissues. Data were presented yesterday by Brian H. Kushner, MD, of the Memorial Sloan-Kettering Cancer Center in New York, during a poster session at the Advances in Neuroblastoma Research Conference which is being held in Toronto , Canada . The Study This was an open-label dose-escalating Phase 1 trial to assess toxicity and efficacy of perifosine, given in monotherapy to patients with neuroblastoma (clinicaltrials.gov NCT00776867). Patients were dosed using 50mg tablets and received a loading dose (100-200mg/m2) of perifosine on day1, followed by daily maintenance doses (50-75mg/m2) until progressive disease or dose-limiting toxicity. Disease evaluation was every 8 weeks. The poster reported on the outcome of 24 patients treated to date; patients had a median age of8.7 years (range 4.7 to 33.5) and a median disease duration of 4.6 years (range 2.5 to 8.0). Three patients were treated for neuroblastoma refractory to … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Aeterna Zentaris: Phase 1 Results Show Perifosine's Activity Against Neuroblastoma

Celgene Provides Regulatory Update

Posted: Published on June 21st, 2012

More Topics: Choose a Sector Accounting Firms Advertising/Media/Communications Capital CEO/Board General Business Health/Biotech Internet/Technology Investment Firms Law Firms Mergers & Acquisitions Money Managers People Private Companies Public Companies Venture Capital Posted June 21, 2012 Application for new indication for REVLIMID (lenalidomide) in newly-diagnosed and maintenance multiple myeloma has been withdrawn from CHMP; Plans to re-submit with more mature data Pomalidomide NDA for patients with relapsed and refractory multiple myeloma accepted for standard review by U.S. FDA, PDUFA date set for Feb. 10, 2013; MAA for patients with relapsed and refractory multiple myeloma submitted to the EMA 2012 guidance and 2015 financial targets reaffirmed Conference call to be held at 8:30 a.m. EDT, available by webcast BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Srl, a subsidiary of Celgene Corporation (NASDAQ: CELG), is providing a regulatory update for REVLIMID (lenalidomide) and pomalidomide as treatments for multiple myeloma. We have decided to withdraw the new indication submission to the Committee for Medicinal Products for Human Use (CHMP) for REVLIMID (lenalidomide), which was intended for the maintenance treatment of newly diagnosed multiple myeloma patients who have not progressed following initial treatment with melphalan, prednisone and REVLIMID (lenalidomide), or maintenance therapy following autologous stem cell transplantation. In response … Continue reading →

Posted in FDA Stem Cell Trials | Comments Off on Celgene Provides Regulatory Update

Cryo-Save Group N.V. awards researcher at grand opening of its new headquarters

Posted: Published on June 21st, 2012

The leading international family stem cell bank, Cryo-Save, celebrates the grand opening of its brand new headquarters office in Zutphen, the Netherlands, by honoring PhD. T.H.J. Nijhuis with the Young Investigator Award on June 22nd. Cryo-Save`s headquarters, located in Zutphen, the Netherlands, is celebrating the grand opening of its brand new, fully-renovated headquarters. On June 22nd, Arnoud van Tulder, CEO of Cryo-Save, and attorney-at-law C. Bieze, deputy in the province of Gelderland, will officially open the company`s new global headquarters office. To mark the occasion, the company will grant PhD. T.H.J. Nijhuis, winner of the Cryo-Save Young Investigator Award, a prize of 5,000 euros. Mr. Nijhuis has focused his most recent research on umbilical cord mesenchymal stem cells and pursues his work at the Erasmus Medical Center, part of the Erasmus University of Rotterdam, the Netherlands. Arnoud van Tulder, CEO of Cryo-Save, says "We are proud to name Mr. T.H.J. Nijhuis, as the winner of the Cryo-Save Young Investigator Award. Research is a cornerstone of the stem cell industry, and it`s advancements like that of Mr. T.H.J. Nijhuis that makes us so optimistic for the future." As part of Cryo-Save`s educational and community outreach efforts, the Cryo-Save Young Investigator Award … Continue reading →

Comments Off on Cryo-Save Group N.V. awards researcher at grand opening of its new headquarters

Muscular dystrophy: MG53 protein is shown to repair cell and tissue damage

Posted: Published on June 21st, 2012

ScienceDaily (June 20, 2012) Throughout the lifecycle, injury to the body's cells occurs naturally, as well as through trauma. Cells have the ability to repair and regenerate themselves, but a defect in the repair process can lead to cardiovascular, neurological, muscular or pulmonary diseases. Recent discoveries of key genes that control cell repair have advanced the often painstaking search for ways to enhance the repair process. A new study by researchers from the University of Medicine and Dentistry of New Jersey (UMDNJ)-Robert Wood Johnson Medical School reports that the protein MG53, previously shown to be the key initiator in the cell membrane repair process, has the potential to be used directly as a therapeutic approach to treating traumatic tissue damage. "We studied the use of MG53 in treating muscular dystrophy by targeting the protein directly to the damaged muscle. The direct application of MG53 slowed the development of the disease by repairing damaged muscle membranes," said Noah Weisleder, PhD, assistant professor of physiology and biophysics and corresponding author of the study. "Our findings also suggest that MG53 could be used in regenerative medicine to treat other human diseases in which traumatic cell injury occurs." The study established methods to produce … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on Muscular dystrophy: MG53 protein is shown to repair cell and tissue damage

AVI BioPharma and Parent Project Muscular Dystrophy Team Up to Run Seattle Marathon & Raise Money to End Duchenne

Posted: Published on June 21st, 2012

Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith. SOURCE Parent Project Muscular Dystrophy HACKENSACK, N.J., June 20, 2012 /PRNewswire-USNewswire/ -- AVI BioPharma is teaming up with Parent Project Muscular Dystrophy (PPMD)'s endurance program, Run For Our Sons, to participate in the Rock 'n' Roll Seattle Marathon & Half Marathon on June 23, 2012. The goal is to raise money and awareness to help end Duchenne muscular dystrophy (Duchenne), the most common form of muscular dystrophy. (Logo: http://photos.prnewswire.com/prnh/20100119/DC39975LOGO) AVI and PPMD have a long history of working together to develop treatments that may help to prolong the lives of those living with Duchenne. "PPMD has always been grateful to the dedication AVI has shown to the Duchenne community as they continue to work on treatments that will help our sons live longer, stronger lives," said Pat Furlong, PPMD's President & Founder. "Now they are taking that dedication a step further by lacing up their running shoes and pounding the streets of Seattle to help raise awareness and end Duchenne." Participating alongside the AVI team … Continue reading →

Posted in Muscular Dystrophy Treatment | Comments Off on AVI BioPharma and Parent Project Muscular Dystrophy Team Up to Run Seattle Marathon & Raise Money to End Duchenne

Joining – The Son-Rise Program – Video

Posted: Published on June 21st, 2012

20-06-2012 08:10 The Son-Rise Program technique of Joining is at the heart of our methadology. Joining helps create a strong bond and relationship and connection with your childs world .Each time we join our children we are communicating to them that we love them and that we are not so different from them, inspiring them to want to connect with us.This video gives three pointers on how to effectivily join your child in their repititious activities. Read more: Joining - The Son-Rise Program - Video … Continue reading →

Comments Off on Joining – The Son-Rise Program – Video

"Brain Pacemaker" Effective for Years Against Parkinson's Disease

Posted: Published on June 21st, 2012

Newswise MAYWOOD, Il. -- A "brain pacemaker" called deep brain stimulation (DBS) remains an effective treatment for Parkinson's disease for at least three years, according to a study in the June 2010 online issue of Neurology, the medical journal of the American Academy of Neurology. But while improvements in motor function remained stable, there were gradual declines in health-related quality of life and cognitive abilities. First author of the study is Frances M. Weaver, PhD, who has joint appointments at Edward Hines Jr. VA Hospital and Loyola University Chicago Stritch School of Medicine. Weaver was one of the lead investigators of a 2010 paper in the New England Journal of Medicine that found that motor functions remained stable for two years in DBS patients. The new additional analysis extended the follow-up period to 36 months. DBS is a treatment for Parkinson's patients who no longer benefit from medication, or who experience unacceptable side effects. DBS is not a cure, and it does not stop the disease from progressing. But in the right patients, DBS can significantly improve symptoms, especially tremors. DBS also can relieve muscle rigidity that causes decreased range of motion. In the DBS procedure, a neurosurgeon drills a … Continue reading →

Posted in Parkinson's Treatment | Comments Off on "Brain Pacemaker" Effective for Years Against Parkinson's Disease

Device Calms Parkinson's Tremor for 3+ Years

Posted: Published on June 21st, 2012

Quality of Life, Daily Living Did Not Improve in Study June 20, 2012 -- For some people with Parkinson's disease, deep brain stimulation can have immediate and dramatic effects on tremors, rigidity, balance, and other motor symptoms. Now new research shows that these benefits may last at least three years. The findings appear online in Neurology. Deep brain stimulation uses a battery-operated device to deliver electrical impulses -- similar to a pacemaker for the heart -- to areas of the brain that control movement. The impulses are thought to block abnormal signals that cause many of the movement problems (motor symptoms) of Parkinson's. This procedure is typically reserved for individuals who no longer respond to their Parkinson's medications or who experience unacceptable side effects from them. According to the new findings, this treatment helped with motor symptoms such as tremor, but individuals did show gradual declines over time in their quality of life, ability to perform tasks of daily living, and thinking skills. "This study looked past the immediate 'wow effect,'" says Michele Tagliati, MD. He wrote an editorial accompanying the new study. "Now we want to know what we can expect over the next 10 years, and this starts … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Device Calms Parkinson's Tremor for 3+ Years

Neil Cavuto Blasts ‘Horses’ Asses’ At MSNBC For Mocking Ann Romney’s Horseback MS Treatment

Posted: Published on June 21st, 2012

video I told myself I wouldnt butt in, Neil Cavuto told the audience today, before addressing those from a network with MS in their name over their mockery of Ann Romneys horseback riding. Romney uses horses for treating her multiple sclerosis an illness Cavuto too has, which led him to explain the legitimacy of this treatment and chide the condescending, sanctimonious twits who refuse to acknowledge the legitimacy of MS as a disease and the need to deal with its shortcomings. RELATED: Neil Cavuto Defends President Obamas Family Values And Commitment To Fatherhood Because I have MS, my comments might be taken with a grain of pity salt and more than a hint of sympathy bias. Well, guilty as charged, Cavuto admitted candidly, explaining that this was why he tried to avoid commenting, but Ive had enough of condescending commentators on another news channel, and was concerned that their comments risk being accepted by an audience that might not know the facts that well. Explaining that several medical sources find some good in using horseback riding to treat problems with walking in those with MS, he reiterated that this is a legitimate therapy not one he uses, he joked, because … Continue reading →

Posted in MS Treatment | Comments Off on Neil Cavuto Blasts ‘Horses’ Asses’ At MSNBC For Mocking Ann Romney’s Horseback MS Treatment

Merck Serono Celebrates the 50-Year Anniversary of Neurobion

Posted: Published on June 21st, 2012

GENEVA, June 21, 2012 /PRNewswire/ -- Merck Serono, a division of Merck in Darmstadt, Germany, today announces that the company is celebrating the 50th anniversary of Neurobion(R), one of the first Vitamin B combinations worldwide. On this occasion, the company and its affiliates worldwide will organize educational activities and information sessions for healthcare professionals to draw attention to the main symptoms and side effects of a lack of B vitamins. Vitamin-B deficiencies may have various degrees of severity. They may be due to several conditions including among others a vegetarian diet or pathologies like diabetes or alcoholism [2,3,4,5]. Lack of these vitamins can remain undetected for many years. The diagnosis is often made accidentally from associated complications. Early detection aims at preventing the effects of the deficiency and its long-term complications. The role of a B-vitamin combination for the treatment of the various clinical manifestations of the deficiency, including neuropathies, is supported by several research papers[6,7,8]. Neurobion(R) is indicated in vitamin deficiencies involving Vitamin B1, B6 or B12 depending upon the combination approved in each country. Some of the Neurobion(R) brands available in certain countries include diclofenac (Dolo-Neurobion(R)), dexamethasone (Dexa-Neurobion(R)) or gabapentin (Gavindol(R)) in addition to the Vitamin B combinations, … Continue reading →

Comments Off on Merck Serono Celebrates the 50-Year Anniversary of Neurobion

Page 6,748«..1020..6,7476,7486,7496,750..6,7606,770..»